Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
2,249.29
0.04 EUR
1.14 M EUR
158.15 M EUR
13.12 M
About PHARMA MAR, S.A.
Sector
CEO
José Maria Fernández de Sousa-Faro
Headquarters
Colmenar Viejo
Website
Founded
1986
ISIN
ES0169501022
FIGI
BBG00BBVX6G7
Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It operates through the following segments: Oncology, Diagnostics, and RNAi. The Oncology segment focuses to the group undertakings whose object is to research, develop, and market anti-tumour drugs. The Diagnostics segment focuses in the development and marketing of diagnostic kits. The RNAi segment develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was founded by José Maria Fernández de Sousa-Faro on April 30, 1986 and is headquartered in Colmenar Viejo, Spain.
Pharmamar PHMGood morning, today I present the analysis of PHM, a Spanish company pharmamar in the race for the vaccine against Covid19.
It is being a great trading year for this company.
The bullish structure marked by the yellow arrow has been broken, but the new structure, the bearish one, has not yet consoli
Pharmamar may reach 7,06€ +50%It seems that Pharmamar may reach 7,06€ (+50% from current price) after activating an iSHS and improving its rating.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PMRA is 76.40 EUR — it has increased by 0.19% in the past 24 hours. Watch PHARMA MAR SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange PHARMA MAR SA stocks are traded under the ticker PMRA.
PMRA stock has fallen by −1.06% compared to the previous week, the month change is a 5.64% rise, over the last year PHARMA MAR SA has showed a 79.43% increase.
We've gathered analysts' opinions on PHARMA MAR SA future price: according to them, PMRA price has a max estimate of 95.00 EUR and a min estimate of 29.60 EUR. Watch PMRA chart and read a more detailed PHARMA MAR SA stock forecast: see what analysts think of PHARMA MAR SA and suggest that you do with its stocks.
PMRA reached its all-time high on Oct 16, 2020 with the price of 143.90 EUR, and its all-time low was 7.92 EUR and was reached on Jun 21, 2007. View more price dynamics on PMRA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
PMRA stock is 4.25% volatile and has beta coefficient of 1.35. Track PHARMA MAR SA stock price on the chart and check out the list of the most volatile stocks — is PHARMA MAR SA there?
Today PHARMA MAR SA has the market capitalization of 1.40 B, it has increased by 4.44% over the last week.
Yes, you can track PHARMA MAR SA financials in yearly and quarterly reports right on TradingView.
PHARMA MAR SA is going to release the next earnings report on Mar 3, 2025. Keep track of upcoming events with our Earnings Calendar.
PMRA earnings for the last quarter are 0.22 EUR per share, whereas the estimation was 0.20 EUR resulting in a 7.32% surprise. The estimated earnings for the next quarter are −0.37 EUR per share. See more details about PHARMA MAR SA earnings.
PHARMA MAR SA revenue for the last quarter amounts to 45.85 M EUR, despite the estimated figure of 45.77 M EUR. In the next quarter, revenue is expected to reach 34.80 M EUR.
PMRA net income for the last quarter is 3.90 M EUR, while the quarter before that showed 1.24 M EUR of net income which accounts for 215.60% change. Track more PHARMA MAR SA financial stats to get the full picture.
PHARMA MAR SA dividend yield was 1.58% in 2023, and payout ratio reached 1.02 K%. The year before the numbers were 0.82% and 19.25% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PHARMA MAR SA EBITDA is 434.00 K EUR, and current EBITDA margin is 0.26%. See more stats in PHARMA MAR SA financial statements.
Like other stocks, PMRA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PHARMA MAR SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PHARMA MAR SA technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PHARMA MAR SA stock shows the buy signal. See more of PHARMA MAR SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.